We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+31.65%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$588M
AUM Growth
+$90.2M
Cap. Flow
-$14.6M
Cap. Flow %
-2.49%
Top 10 Hldgs %
70.6%
Holding
33
New
4
Increased
8
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$40.5M
2
BLRX
BioLineRX
BLRX
+$18.8M
3
CTMX icon
CytomX Therapeutics
CTMX
+$16.4M
4
LOXO
Loxo Oncology, Inc
LOXO
+$13.2M
5
XOMA
Xoma
XOMA
+$6.17M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$41.3M
2
ARRY
Array Biopharma Inc
ARRY
+$23.7M
3
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$17.6M
4
ESPR
Esperion Therapeutics
ESPR
+$8.92M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$8.5M

Sector Composition

Rank Sector Weight
1 Healthcare 75.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANTH
26
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.43M 0.58%
1,006,509
+998,722
+12,826% +$4.72M
OREX
27
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.53M 0.43%
734,976
– –
FLNA
28
Filana Therapeutics
FLNA
$46.4M
$2.04M 0.35%
325,507
– –
RGLS
29
DELISTED
Regulus Therapeutics
RGLS
$1.03M 0.17%
+5,192
New +$988K
ESPR
30
DELISTED
Esperion Therapeutics
ESPR
– –
-712,770
Closed -$8.92M
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-149,177
Closed -$8.5M
CLCD
32
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-484,335
Closed -$17.6M
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2017 Portfolio in Review

As of Q1 2017, BVF Inc held 33 positions worth $588M, up 18% from $498M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

BVF Inc's Q1 2017 filing shows 4 new, 8 increased, 8 reduced and 3 closed positions. Its largest new stake was AnaptysBio: 1,738,600 shares worth $48.2M. The largest sale was Blueprint Medicines, an estimated $41.3M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 77% a quarter earlier.

  • BVF Inc's largest Q1 2017 buy was AnaptysBio: 1,738,600 shares worth $48.2M.
  • BVF Inc added most to CytomX Therapeutics in Q1 2017, an estimated $16.4M increase.
  • BVF Inc's biggest Q1 2017 reduction was Blueprint Medicines, cutting an estimated $41.3M.
  • BVF Inc fully exited CoLucid Pharmaceuticals, Inc. in Q1 2017, selling an estimated $17.6M.
  • BVF Inc's ten largest holdings make up 71% of its $588M portfolio in Q1 2017.
  • BVF Inc opened 4 new positions and closed 3 in Q1 2017.
  • BVF Inc's portfolio value rose 18% quarter-over-quarter to $588M.

Based on BVF Inc's 13F filing for Q1 2017, filed 15 May 2017.